New results from researchers at the Centre for Pathobiochemistry and Genetics at the Medical University of Vienna show that a protein called mTORC2, which is the target of newly developed cancer drugs, is not even active in colorectal cancer.
In cooperation with the BMW Group and HOFER KG, the new Josef Ressel Centre at the University of Applied Sciences Upper Austria Campus Steyr will carry out research until the end of 2023 on developing a monitoring tool to achieve close to real-time visualisation of value networks.
